RNA interference using c-Myc-conjugated nanoparticles suppresses breast and colorectal cancer models

Molecular Cancer Therapeutics

Volumn 14, Issue 5, 2015, Pages 1259-1269

  Tangudu, Naveen K ^a   Verma, Vinod K ^a   Clemons, Tristan D ^b   Beevi, Syed S ^a   Hay, Trevor ^c   Mahidhara, Ganesh ^a   Raja, Meera ^c   Nair, Rekha A ^d   Alexander, Liza E ^d   Patel, Anant B ^a   Jose, Jedy ^a   Smith, Nicole M ^e   Zdyrko, Bogdan ^f   Bourdoncle, Anne ^e   Luzinov, Igor ^f   Iyer, K Swaminathan ^b   Clarke, Alan R ^c   Dinesh Kumar, Lekha ^a  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d REGIONAL CANCER CENTRE   (India)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f Clemson University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CASPASE 3; MYC PROTEIN; PLASMID DNA; POLYETHYLENEIMINE DERIVATIVE; POLYGLYCIDAL METHACRYLATE; POLYMETHACRYLIC ACID DERIVATIVE; PROTEIN P53; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANTISENSE OLIGONUCLEOTIDE; NANOCONJUGATE; POLY(PROPYLENEIMINE); POLYPROPYLENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CELL ADHESION; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DNA INTEGRATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EMBRYO; ENDOCYTOSIS; EX VIVO STUDY; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER FUNCTION TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; RETICULOENDOTHELIAL SYSTEM; RNA INTERFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER TRANSPLANTATION; CHEMISTRY; COLORECTAL NEOPLASMS; FEMALE; GENETICS; HEK293 CELL LINE; JURKAT CELL LINE; MCF 7 CELL LINE; PROCEDURES; RNAI THERAPEUTICS; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE SILENCING; HEK293 CELLS; HUMANS; JURKAT CELLS; MCF-7 CELLS; MICE; NANOCONJUGATES; NEOPLASM TRANSPLANTATION; NIH 3T3 CELLS; OLIGONUCLEOTIDES, ANTISENSE; POLYPROPYLENES; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; RNAI THERAPEUTICS;

EID: 84942107099     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0970     Document Type: Article

References (29)

1. Bishop JM. Retroviruses and cancer genes. Adv Cancer Res 1982;37:1-32.
2. Elend M., Eilers M. Cell Growth: Downstream of Myc - To Grow or To Cycle? Curr Biol 1999;9:R936-8.
3. Zhang L, Hou Y, Ashktorab H, Gao L, Xu Y, Wu K, et al. The impact of CMYC gene expression on gastric cancer cell. Mol Cell Biochem 2010;344:125-35.
4. Caplen NJ. Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther 2004;11:1241-48.
5. DykxhoornDM, Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med 2005;56:401-23.
6. Kumar LD, Clarke AR. Gene manipulation through the use of small interfering RNA (siRNA): From in vitro to in vivo applications. Adv Drug Deliver Rev 2007;59:87-100.
7. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-17.
8. Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH. Delivery of RNA interference. Cell Cycle 2006;5:2103-9.
9. Siolas D, Lerner C, Burchard J, Ge W, Linsley PS, Paddison PJ, et al. Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 2005;23:227-31.
10. Jensen SA, Day ES, Ko CH, Hurley LA, Luciano JP, Kouri FM, et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med 2013;5:209ra152.
11. Lungwitz U, Breunig M, Blunk T, Gopferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 2005;60:247-66.
12. Boussif O, Lezoualch F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A Versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 1995;92:7297-301.
13. Moghimi SM, Symonds P, Murray JC, Hunter AC, DebskaG, Szewczyk A. A two-stage poly (ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther 2005;11:990-5.
14. GrzelinskiM, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Hobel S, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006;17:751-66.
15. Breunig M, Lungwitz U, Liebl R, Goepferich A. Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc Natl Acad Sci U S A 2007;104:14454-9.
16. Evans CW, Fitzgerald M, Clemons TD, House MJ, Padman BS, Shaw JA, et al. Multimodal analysis of PEI-mediated endocytosis of nanoparticles in neural Cells. ACS Nano 2011;5:8640-8.
17. Iyer KS, Zdyrko B, Malz H, Pionteck J, Luzinov I. Polystyrene layers grafted to macromolecular anchoring layer. Macromolecules 2003;36:6519-6526.
18. Sun S, Zeng H, Robinson DB, Raoux S, Rice PM, Wang S X, et al. Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles. J Am Chem Soc 2004;126:273-9.
19. Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, et al. Poly (ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009;69:3850-5.
20. Sansom OJ, Reed KR, Hayes AJ, Ireland H, Brinkmann H, Newton IP, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 2004;18:1385-90.
21. Ramesh J, Salman A, Hammody Z, Cohen B, Gopas J, Grossman N, et al. FTIR microscopic studies on normal and H-ras oncogene transfected cultured mouse fibroblasts. Euro Biophys J 2001;30:250-5.
22. Kopatz I, Remy JS, Behr JP. A model for non-viral gene delivery: through syndecan adhesion molecules and powered by actin. J Gene Med 2004;6:769-76.
23. Zhao N, Qi J, Zeng Z, Parekh P, Chang CC, Tung CH, et al. Transfecting the hard-to-transfect lymphoma/leukemia cells using a simple cationic polymer nanocomplex. J Control Release 2012;159:104-10.
24. Issabekova A, Berillo O, Regnier M, Anatoly I. Interactions of intergenic microRNAs with mRNAs of genes involved in carcinogenesis. Bioinformation 2012;8:513-8
25. Kim D H, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007;8:173-84.
26. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011;2:281-98.
27. Tsyalkovsky V, Klep V, Ramaratnam K, Lupitskyy R, Minko S, Luzinov I. Fluorescent reactive core-shell composite nanoparticles with a high surface concentration of epoxy functionalities. Chem Mater 2008;20:317-25.
28. Sonawane ND, Szoka FC Jr, Verkman AS. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem 2003;278:44826-31
29. Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012;4:128ra39.